Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL. Issue 8 (October 2016)
- Record Type:
- Journal Article
- Title:
- Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL. Issue 8 (October 2016)
- Main Title:
- Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL
- Authors:
- Engelstein, Roni
Merims, Sharon
Eisenberg, Galit
Cohen, Jonathan
Frank, Stephen
Hamburger, Tamar
Frankenburg, Shoshana
Ron, Ilan
Isacson, Ruth
Grenader, Tal
Steinberg, Hanna
Cohen, Cyrille J.
Peretz, Tamar
Lotem, Michal - Abstract:
- Abstract : CD8 lymphocytes are mandatory mediators of tumor regression. To enhance their specific antitumor activity, we aimed to improve a melanoma cell-based vaccine by transfecting it with 4-1BB ligand, a costimulatory and immune modulatory molecule. Thirty-four American Joint Committee on Cancer (AJCC) stage IIB–IV patients were vaccinated with a melanoma antigen-rich cell line engineered to express HLA-A2 and 4-1BBL (M20/A2/BBL). Twelve serially recruited patients were monitored for interferon γ expression and CD107a mobilization before and after vaccination. Thirty-three patients remained alive, with an estimated mean overall survival of 26.2 months. No grade 3–4 adverse events were encountered. Immune monitoring detected an increase in circulating antimelanoma CD8 T cells in 9 of 12 patients, which were significantly stimulated by the parental melanoma, reflecting a relevant antitumor response. The results from this study show that the costimulatory 4-1BB ligand fortifies an antigen-rich melanoma cell line with enhanced antigen-specific stimulation of CD8 T cells. The use of a costimulatory molecule as part of a vaccine confers a selective increase of T-cell subsets with antimelanoma reactivity, which in some cases were characterized for their epitope specificity. Abstract : Supplemental Digital Content is available in the text.
- Is Part Of:
- Journal of immunotherapy. Volume 39:Issue 8(2016:Oct.)
- Journal:
- Journal of immunotherapy
- Issue:
- Volume 39:Issue 8(2016:Oct.)
- Issue Display:
- Volume 39, Issue 8 (2016)
- Year:
- 2016
- Volume:
- 39
- Issue:
- 8
- Issue Sort Value:
- 2016-0039-0008-0000
- Page Start:
- Page End:
- Publication Date:
- 2016-10
- Subjects:
- 4-1BB ligand -- melanoma vaccine -- immune monitoring -- interferon-gamma -- CD107a
Immunotherapy -- Periodicals
Immunotherapy -- Periodicals
Neoplasms -- therapy -- Periodicals
Electronic journals
Electronic journals
615.37 - Journal URLs:
- http://www.immunotherapy-journal.com/ ↗
http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=00002371-000000000-00000 ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/CJI.0000000000000138 ↗
- Languages:
- English
- ISSNs:
- 1524-9557
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5005.040000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 5136.xml